Hetero launches Favipiravir in India to treat COVID-19

Hetero launches Favipiravir in India to treat COVID-19

Hetero Pharmaceuticals has launched the generic version of antiviral drug favipiravir under the brand name ‘Favivir’ to treat mild to moderate COVID-19.

The company received the manufacturing and marketing approval for the drug from the  Drug Controller General of India (DCGI). Favivir is the second drug developed by Hetero after Covifor (remdesivir) used in the treatment of COVID-19.

Hetero’s Favivir is priced at R 59 per tablet and is marketed and distributed by Hetero Healthcare Limited, the company said in a statement.